Mesoblast Limited (NASDAQ:MESO) has been performing well with its Ryoncil drug, bringing in $30 million in gross revenue in the fiscal second quarter. Jefferies upgraded the stock to Buy and increased the share price target to AUD3.30, citing optimism in the drug’s performance and potential for growth.

Ryoncil by Mesoblast Limited (NASDAQ:MESO) secured a J-Code from Medicare and Medicaid services, allowing for reimbursements and expanded availability in the US. The drug is the first of its kind to receive this designation, benefiting pediatric patients undergoing stem cell transplants.

While Mesoblast Limited (NASDAQ:MESO) shows promise as an investment, some AI stocks may offer higher returns with limited downside risk. Consider exploring opportunities in the AI sector for potential growth and profitability beyond traditional pharmaceutical investments.

Read more at Yahoo Finance: Mesoblast (MESO) Sees Optimism From Analysts